Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience

A phase II trial of intra-patient dose escalated-sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)

(2017) R. J. Amato et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment

(2009) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

(2009) Antonius A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

Sorafenib for Metastatic Renal Cancer

(2008) Rachel P. Riechelmann et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE